title: Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
abstract: Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment.
authors.affiliation: Department of Neurology, State University of New York Upstate Medical University, Syracuse, NY, United States. kom@upstate.edu
authors.forename: Melissa W
authors.initials: MW
authors.lastname: Ko
authors.forename: Madhura A
authors.initials: MA
authors.lastname: Tamhankar
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Volpe
authors.forename: David
authors.initials: D
authors.lastname: Porter
authors.forename: Cindy
authors.initials: C
authors.lastname: McGrath
authors.forename: Steven L
authors.initials: SL
authors.lastname: Galetta
mesh_terms: D000700:Analgesics / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy; D009900:Optic Nerve / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D000700:Analgesics; D008942:Mitoxantrone